Therefore, phospholipid-binding of Angiomotin is a key regulatory mechanism of TJ/polarity disassembly during epithelial dedifferentiation (e.g., EMT), qualifying Angiomotin as an oncogene in some cancer types (reviewed by Lv et al., 2017). This evidence concerns the gene AMOT and cancer.